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ABSTRACT   
 
Monocytic cells, including macrophages and dendritic cells, exist in different activation states 
that are critical to the regulation of antimicrobial immunity. Many pandemic viruses are  
monocytotropic, including porcine reproductive and respiratory syndrome virus (PRRSV), which 
directly infects subsets of monocytic cells and interferes in antiviral responses. To study antiviral 
responses in PRRSV-infected monocytic cells, we characterized inflammatory cytokine  
responses and genome-wide profiled signature genes to investigate response pathways in  
uninfected and PRRSV-infected monocytic cells at different activation states. Our findings  
showed suppressed interferon (IFN) production in macrophages at non-antiviral states and an  
arrest of lipid metabolic pathways in macrophages at antiviral states. Importantly, porcine  
monocytic cells at different activation states were susceptible to PRRSV and responded  
differently to viral infection.  B ased on gene ontology analysis, two approaches were used to  
potentiate antiviral activity: 1) pharmaceutical modulation of cellular lipid metabolism and 2) in  
situ PRRSV replication-competent expression of IFN-α; both approaches significantly  
suppressed exogenous viral infection in monocytic cells. In particular, the engineered IFN- 
expressing PRRSV strain eliminated exogenous virus infection and sustained cell viability at 4  
days post infection in macrophages.  T hese findings suggest an intricate interaction of viral  
infection with activation status of porcine monocytic cells.  An understanding and integration of  
antiviral infection with activation status of monocytic cells may provide a means of potentiating  
antiviral immunity.     
  
IMPORTANCE:   
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Activation statuses of monocytic cells including monocytes, macrophages (MФs) and dendritic  
cells (DCs) are critically important for antiviral immunity. Unfortunately, the activation status of  
porcine monocytic cells or how cell activation status functionally interacts with antiviral  
immunity remains largely unknown. This is a significant omission because many economically  
important porcine viruses are monocytotropic including our focus PRRSV, which alone causes  
near $800M economic loss annually in the US swine industries. PRRSV is ideal for deciphering  
how monocytic cell activation statuses interact with antiviral immunity, because it d irectly  
infects subsets of monocytic cells and subverts overall immune responses. In this study, we  
systematically investigate the activation status of porcine monocytic cells to determine intricate  
interaction of viral infection with activation statuses, and functionally regulate antiviral  
immunity within the framework of the activation paradigm. Our findings may provide a means  
of potentiating antiviral immunity and leading to novel vaccines for PRRS prevention.    
  
INTRODUCTION  
  
Monocytic cells, including blood monocytes (BMs), tissue macrophages (MΦs), and dendritic  
cells (DCs), originate from common myeloid progenitor cells (1). After origin, they circulate to  
locate throughout the body, and specialize into a variety of activation statuses to functionally  
regulate defensive responses and immune homeostasis (1-5). The activation status of monocytic  
cells such as in MΦs conventionally has been assigned as classical M1 and alternative M2  
statuses as well as other subtypes (2-4). For instance, classically activated (or M1 status) MΦs  
develop in response to interferon (IFN)-γ and bacterial products such as lipopolysaccharides  
(LPS); M2 status of those MΦs alternatively activated by the Th2 cytokines interleukin (IL)-4 or  
IL-13 in response to parasitic infections, is assigned as the M2a subclass. Accordingly, the other  
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subclasses of M2 cells include M2b obtained by triggering of Fcγ receptors plus the stimulation  
of Toll-like receptors (TLRs) in MΦs, and M2c of deactivation programs elicited by  
immunosuppressive cytokines and hormones such as IL-10, glucocorticoids (GC) and  
transforming growth factor (TGF)-β (2-4). Despite not being well-studied, the M1/M2 activation  
paradigm is represented in both monocytes and DCs (1,5-7). For example, human monocytes are 
divided based on the expression of CD16 with CD16+ monocytes representing M1 cells, which  
are more proinflammatory and microbicidal (5). A similar paradigm has been postulated for DCs  
with type I DCs representing a subset inducing Th1 responses and type II DCs activating Th2  
responses (8,9). Nonetheless, the criteria for DC polarization and associated activation markers  
remain elusive in all species (1,6,7).   
  
Monocytic cells at different activation statuses, as well-characterized in MΦs, functionally exert 79 
phenotypes to regulate inflammation, tissue repair, T- and B-cell proliferation, phagocytosis and  
antimicrobial activity against bacteria and helminthes (3-5). In addition, monocytic cells confer a  
cell-autonomous antiviral state induced upon viral infection or stimulation by viral mimics (10- 
13).  Indeed, stimulation of type I IFN production and expression of IFN-stimulated genes (ISGs)  
for combating virus propagation are hallmarks of the antiviral state (10-15). Subsets of  
monocytic cells typically are among the major producers of type I IF Ns (10-15), and recent  
studies have posited direct interaction between MΦ polarization and viral infection (16-18).  For  
example, HIV and respiratory syncytial virus (RSV) were shown to alter MФ activation statuses  
thus affecting viral pathogenesis and host immune responses (16-18).  In addition, most  
pandemic viral infections cause disease syndromes frequently complicated with co-infection  
from pathogens of other phyla (19-23).  Thus, it is important to integrate the activation status  
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with antiviral states linked to type I IFN production and action (16-19). Understanding the  
relationships among activation statuses and antiviral states not only extends the activation  
paradigm of monocytic cells but also integrates antiviral regulation into the scenario of immune  
responses including inflammation, tissue repair and overall antimicrobial activity (11,17,18,21)   
  
Many of the most economically important animal viruses are monocytotropic (21), including  
porcine reproductive and respiratory syndrome virus (PRRSV), the focus in this study.  PRRSV  
is an enveloped positive-strand RNA virus that directly infects subsets of MΦs and DCs and  
subverts immune responses in monocytic cells, making it ideal for deciphering how monocytic  
cell activation status interacts with antiviral immunity (21,24-28).  Monocytic cells are critical  
for providing early immune surveillance and bridging adaptive antiviral immunity (1-5,7,11).  
Direct infection of monocytic subsets of MФs and DCs by PRRSV inevitably leads to immune  
deviation and likely alters activation statuses (21).  Few studies have focused on the activation  
status of porcine monocytic cells or how cell activation status modulates antiviral immunity 
(27,28).  N otably, in this study we focused on examining gene ontology analysis based on  
comparative transcriptomes revealed in macrophages at different activation statuses upon vi ral  
infection, rather than a transcriptomic comparison between infected and non-infected  
tissues/cells, which has been well-documented in previous studies (29,30). In this context, we  
used a multiplex cytokine assay and transcriptomic RNA-Seq analysis to profile gene response  
pathways in porcine monocytic cells polarized to typical activation statuses and antiviral states.   
We then showed that cells at different activation statuses (including antiviral states) reacted  
differently to PRRSV infection in cytokine production and viral permissiveness. In addition, we  
investigated pharmaceutical and molecular approaches to promote antiviral immunity within the  
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framework of cell activation statuses (2,17,18,21), and showed that a lipid mediator and an IFN- 
expressing PRRSV vector successfully polarized porcine cells toward antiviral protection, which  
may facilitate novel adjuvant/vaccine approaches (21).    
  
MATERIALS AND METHODS  
Animals and isolation of primary cells  
Animal procedures and the isolation of alveolar macrophages and peripheral blood mononuclear 
cells (PBMCs) were conducted as described previously (29, 31-37). PBMCs were isolated using  
a 60% Ficoll-Paque Plus gradient (GE Heathcare, Piscataway, NJ).  M onocytes were isolated  
from PBMCs with an anti-CD14 antibody (Ab) using magnetic beads conjugated with the  
corresponding secondary Ab (Miltenyi Biotec, Auburn, CA), and further phenotyped by a two- 
color immunofluorescence facilitated flow cytometric analysis (38). The mDCs were generated  
by culturing monocytes in the presence of IL-4 and granulocyte-macrophage colony-stimulating  
factor (GM-CSF) for 7 d as previously described (36,37). Lavage fluids were centrifuged at 400  
× g for 15 min to collect cells and further isolate MФs by plastic adherence (36,37). Properties of  
both macrophages and mDCs were verified according to previously established procedures  
(35,36).  Cells were used immediately or cryopreserved in Recovery™ cell culture freezing  
medium (Invitrogen, Carlsbad, CA).   
  
Cell polarization and cytokine phenotyping  
 Mediators and conditions for polarization of porcine monocytic cells were applied as previously  
described (1-5,29). In brief, MФs and DCs were stimulated with the mediators LPS, IFNγ, IL-4,  
IL-10, IFNα and IFNβ at 20 ng/ml, and blood monocytes (BMs) were stimulated with either  
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GMCSF at 50 ng/ml or MCSF at 100 ng /ml for 30 h . All mediators (purchased from R&D  
Systems at Minneapolis, MN, or Sigma-Aldrich, St. Louis, MO) were dissolved in 1×Dulbecco's 
PBS (DPBS, Invitrogen) containing 1% bovine serum albumin (BSA, Fraction V, Cold-ethanol 
precipitated, Sigma) and applied (1:100) to the cultured cells. For control cells, only BSA in  
DPBS was added to the cultures. Cells were then thoroughly washed and replenished with fresh 
medium for 16 h. Culture supernatants from an equal amount of cells from each treatment were  
collected, and secreted cytokines were measured using a S earchLight chemiluminescent  
multiplex assay (Aushon BioSystems, Billerica, MA) (24). Data were normalized as fold  
changes relative to the control cells and presented as means of three independent replicates.  
Alternatively, polarized MФs and DCs were infected with PRRSV strain incorporated with a red  
fluorescent protein (Ds-Red) for 16 h (29). The cells were then fixed with 4% formaldehyde in  
PBS, and PRRSV-positive cells and the expression of CD163 (a scavenger receptor critical to  
PRRSV cell entry) were examined using both two-color fluorescent flow cytometry and    
fluorescent microscopy. The antibody for CD163 detection was directly using the FITC- 
conjugated mouse mAb (Clone 2A10/11, AbD Serotec, Raleigh, NC) for evaluation with flow  
cytometry, or together using indirect labeling of CD163 mAb by an Alexa Fluor® 488- 
conjugated anti-mouse IgG (Invitrogen) for imaging with a fluorescent microscopy.  The  
CD163-positive cells in pictures were counted with ImageJ at http://imagej.nih.gov/ij/.         
  
Genome-wide profiling marker genes related to macrophage activation statuses  
The expression of marker genes relative to each activation status and antiviral state were  
revealed using next-generation transcriptome sequencing (RNA-Seq) for genome-wide screening  
and confirmed family-wide using real-time RT-PCR assays. For RNA-Seq, equal quantities of  
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primary alveolar macrophages were polarized for 30 h i ndividually with the verified procedure  
described above and further infected for 5 h w ith a PRRSV strain as previously described (29).   
RNA preparation, RNA-Seq performance and DEG analysis were done as previously described  
(29). In brief, 3×107 cells of each activation status (including the control DPBS-mock  
stimulation) were pooled from three technical replicates representing cells obtained from four  
outbreed pigs. Instead of applying the RNA-Seq procedure individually to each biological or  
technical replicate, replicates were pooled before proceeding to RNA-Seq analysis.  In this case, 
the differentially expressed genes between two samples were assayed based on an algorithm as  
described previously (29).  Functional classification of genes was conducted through Gene 
Ontology using the DAVID web tool (29,30,39). This method maps all DEGs to GO terms in the  
database (http://www.geneontology.org/), calculates gene numbers for every term, and then uses  
a hypergeometric test to find significantly enriched GO terms in DEGs compared with the  
genome background. The calculating formula is:  ,  N is the number of all genes  
with GO annotation; n i s the number of DEGs in N; M is the number of all genes that are  
annotated to the certain GO terms; and m is the number of DEGs in M. The calculated p-value  
went through Bonferroni Correction using the corrected p-value ≤ 0.05 as a threshold. GO terms  
fulfilling this condition were defined as significantly enriched GO terms in DEGs; this analysis  
recognizes the main biological functions that DEGs exercise.  In addition, the expression of some  
genes was verified using real-time RT-PCR assays and a two-dimensional difference in gel  
electrophoresis (2D-DIGE) proteomic procedure (Applied Biomics, Inc., Hayward, CA) (28).  
  
  
Antiviral/activation regulation with a lipid mediator, ToFA  
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A cell-permeable inhibitor of acetyl-CoA carboxylase, 5-(Tetradecyloxy)-2-furoic acid (ToFA,  
Sigma-Aldrich) at 5 μg/ml was added to culture medium containing porcine BMs, MФs, and  
DCs for 30 h (40). Secretion of cytokines in the medium and expression of signature genes were  
analyzed as described above to phenotype the ToFA-induced activation status. The antiviral  
effects of ToFA treatment were evaluated by suppression of PRRSV replication and stimulated  
production of cytokines.   
  
Construction of IFN-expressing PRRS viruses and infectivity analyses  
We have constructed and produced a series of IFN-expressing PRRS viruses for evaluation of the 
effect of in situ expressed IFNs associated with the virus replication. The previously constructed  
IFN-expressing constructs, successfully incorporated the intact coding regions of porcine IFN 
genes of IFNα1, IFN-β, IFNδ3 and IFNω5, and showed in situ production of IFN polypeptides in  
the virus infected cells and inhibition of co-infected PRRSV corresponding to the subtype- 
specific anti-PRRSV activity (37).  A question we confronted for molecular vaccine design,  
however, is how can sufficient PRRSV replication activity be achieved when expressing an IFN  
with high PRRSV antiviral activity.  To address this problem, we inserted a leader linker in front  
of the IFN coding region that encodes a six histidine tag (6XHis) plus a 10-residue polypeptide  
containing a C-terminal cleavage peptide (GKPILFFRLK) of cathepsin D (CSTD), a p rotease  
induced during PRRSV infection in MФs (Y. Sang, unpublished data). Two 36-nt complement  
oligos containing codons optimized for encoding the cathepsin-cleavage peptide were  
synthesized (IDT DNA, Coralville, IA) with EcoR I cloning overhangs at their 5’- and 3’- 
termini.  T he synthetic inserts were ligated into a pHUE expression vector through EcoR I  
cloning site to fuse with the N-terminal vector sequence encoding 6XHis tag and the C-terminal  
IFNα6 coding region (previously cloned through the vector EcoR I and Hind III cloning sites).  
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The cDNA flanking the region coding (His)6-GKPILFFRLK-IFNα6 was amplified from  
authentic clones using a high-fidelity PCR (Phusion, NEB) and two restriction enzyme digestion  
sites (Afl II and Mlu I) were introduced into 5'- and 3'-ends of the coding region. The amplified  
coding region was purified and cloned into the expression cassette of the PRRSV infectious  
cDNA clone, pCMV-P129, following the previously described procedure (37). The rescue,  
titration and infectivity analysis of progeny viruses were performed as described for other  
bioengineered PRRS viruses (37).       
Data analyses: The quality of RNA-Seq data was analyzed in terms of the proportion of gene-  
mapped reads and the saturation/randomness for genome-wide gene coverage using published  
procedures (29,30,-39). Differentially expressed genes [DEGs, with the false discovery rate  
(FDR) ≤ 0.001, fold change > 2] were profiled with an edgeR package (39).  The gene- 
expression data of real-time RT-PCR were normalized against Ct values of internal reference  
genes and control samples (33,34).  Differences between groups were determined by Student's t- 
test.   
  
RESULTS  
Polarization of monocytes, MФs and mDCs in vitro and cytokine phenotyping  
Both forward and reverse approaches have been used to determine the activation statuses of  
porcine monocytic innate immune cells (2-5). In brief, primary tissue MФs, BMs and DCs were  
polarized by well-established activation mediators and the expression of marker genes was  
analyzed at RNA and protein levels (forward). Confirmed signature genes then were used to  
classify the subsets of primary cells or specifically activated cells (reverse).   T o this end, we  
polarized BMs, alveolar MФs and mDCs with LPS and IFNγ for M1, IL-4 for M2a, IL-10 for  
M2c and IFNα/β for the antiviral state (Table 1) (2-5). Porcine monocytic cells were responsive  
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to these mediators and the corresponding cytokines produced elicited the proposed functional  
statuses.  F or example, LPS-/IFNγ-induced M1 MФs (M1-LPS or M1-IFNγ) showed up- 
regulation of proinflammatory cytokines including IL-1β, IL-6 and IL-8; in contrast, IL-4-/IL- 
10-induced M2 cells (M2-IL4 or M2-IL10) displayed down-regulation of these cytokines.  
Interestingly, MФs treated with type I IFNs to induce antiviral states had cytokine production  
patterns compatible with the activation paradigm. In particular, IFNα-treated MФs were similar  
to M1-IFNγ cells and IFNβ-treated MФs were similar to M2-IL10 cells regarding the increase or  
decrease of cytokines. Blood monocytes primed with either GM-CSF or M-CSF showed  
dramatic increases in IL-1β, IL-8, TNFα and IL-10; however, these two early-phase priming  
cytokines showed different responses in regulation of IL-6 and IL-8 (5). Monocyte-derived DCs  
showed a similar tendency except they were less responsive in production of proinflammatory  
cytokines such as IL-1β, IL-6, IL-12 and TNFα; however, all had increased production of IL-8  
indicating a high migrating potential of mDCs (1,6). In addition, IFNβ appeared more active in  
stimulating IL-1β production in mDCs than in alveolar MФs (Table 1).   
  
Family-wide profile of cytokine and chemokine genes related to the activation status of  
porcine MФs upon PRRSV infection   
In addition to evaluating the secreted cytokines, we also used a non-biased RNA-Seq procedure  
to profile the genome-wide response of the cytokine-cytokine receptor system in porcine MФs at  
different activation statuses. Serial assessments for quality control were conducted to verify that  
our RNA-Seq procedure and data met the criteria for genome-wide transcriptomic assays (29).   
As shown in Table 2 and Supplemental Figure S1, family-wide expression of cytokines,  
chemokines and their receptors was detected. Gene expression of inflammatory cytokines  
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including IL-1β, IL-6, IL-8, IL-10, IL-12 and TNFα was consistent with the multiplex assays at  
the protein level, except for the highest expression of the IL-10 gene in MФs at the M1-LPS  
status (Table 1).  In addition to these well-studied inflammatory cytokines, we also showed the  
status-specific expression of other cytokine-related genes in one or two statuses (Table 2 and the  
Supplemental Figure S1). These novel cytokine- or chemokine-related makers included, IL7,  
IL10RA (IL-10 receptor, alpha), IL15RA and CCL21 in the M1-IFNγ status, as well as IL4RA,  
IL6RA, IL10RB, CSF2RB and CXCL4 particularly in the M2-IL10 status. In general, we found  
21–35 cytokine/chemokine-related genes significantly up-regulated in each activation status; the  
M2-IL10 status had the lowest number (21) and M1-LPS status had the highest number (29).  
Notably, most chemokine genes were co-stimulated significantly in both M1-IFNγ and IFNα- 
activated antiviral (MaV-IFNα) statuses. Some cytokine-related genes were specifically  
suppressed in certain activation status, including CCL19 and CCL22 in the IFNγ-M1 status;  
CCL2 and CCL23 in the M2-IL4 status; IL4RA and CCL21 in the M1-LPS status; and IL10RA,  
IL18 and CCL8 in the MaV-IFNα status.  O verall, we identified 96 p orcine transcripts of  
cytokines/chemokines and their receptors, and many of them, such as the genes of five porcine  
IL-17 receptors, were for the first time revealed family-wide at the transcriptional level (Table 2  
and the Supplemental Figure S1). These findings indicate that the RNA-Seq data could be  
exploited for identification of novel transcripts in addition to genome-wide quantitative analyses.  
Toll-like receptors (TLRs) are among the most important cellular receptors to recognize  
pathogen-associated molecular patterns and induce the production of immune effectors including  
cytokines. Annotation of our RNA-Seq data revealed significant regulation of all porcine TLR  
paralogs except TLR5, which was specifically expressed on the basolateral surface of intestinal  
epithelial cells, but not expressed in porcine alveolar macrophages (Supplemental Figure S1C)  
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(21). Corresponding to discoveries in murine macrophages, high expression of TLR2, TLR7 and  
TLR8 was found in cells activated at M1-LPS, MaV-IFNα and M2-IL10 statuses, respectively 
(Figure 1A and Supplemental Figure S1C). Constitutive expression of multiple TLRs (TLR2,  
TLR4, TLR6 and TLR8) was clearly associated with most activation statuses, indicating the  
immunocompetent potency of alveolar macrophages in response to diverse pathogenic stimuli  
(21).  For confirmation, expression of genes of the IL-17, TLRs and GBP families were also  
verified using a RT-PCR protocol (29, and Supplemental Figure S2).     
  
Genome-wide profile of classic and species-specific signature genes associated with the  
activation status of porcine MФs upon PRRSV infection  
Phenotypic manifestation of activation statuses in monocytic cells has been associated with    
various exogenous stimuli and, in turn, endogenous expression of signature genes, including  
intracellular transcription factors, metabolic enzymes, and surface receptors as well as secreted 
cytokine peptides (1-5). A series of typical signature genes has been characterized in  
macrophages at different activation statuses in humans and mice; however, their similarity or  
difference in pigs has not been systematically studied.  Figure 1A shows signature genes 
pertinent to each well-characterized activation status in mice (1-5). Except for the M2b status not  
evaluated herein and CCL13 and CCL18, whose porcine orthologs have not been identified (40),  
most other listed signature genes were identified and showed high expression for each activation  
status.  Notably, the antiviral state (MaV-IFNα) integrated and fit very well in the paradigm of 
MФ activation statuses (Fig. 2A). For example, cells at the MaV-IFNα state were primed  
primarily by type I or type III IFNs and underwent further maturation by TLRs or other receptors  
sensing viral molecular patterns (7,10,12,15,21).  Signature genes characteristic of the antiviral  
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state include the activation of IRF-3/IRF-7 and stimulation of antiviral ISGs (2,7,10,12,15).  
Based on our studies and those of others, we know that induction of the antiviral state is common  
in all monocytic cells (2,10,17,18,21), but whether subsets of monocytes and MФs are preset for 
antiviral responses, such as pDCs showing a natural propensity of IFNα production, is not known  
(11,24).   
  
The unbiased RNA-Seq procedure also allowed us to profile species-specific signature genes  
pertaining to porcine macrophages at different activation statuses. For example, evaluation of  
potential signature genes identified 72 and 234 significant DEGs that were up-regulated only in  
LPS-M1 and IL4-M2 statuses, respectively (Fig. 1B). These potential marker genes include some  
known genes such as CD1B (a MHC protein mediating presentation of lipid antigens to T cells),  
colony-stimulating factor (CSF), and leukemia inhibitory factor (LIF) in addition to transcripts  
with unknown identities (Fig. 1B). Most of these genes have not been studied for regulation of  
activation statuses and antiviral immunity.   
   
PRRSV infection differentially altered cytokine production in macrophages at different  
activation statuses  
Because viruses such as HIV and RSV altered activation statuses in macrophages (16-19), we  
examined whether PRRSV infection interacts differentially with macrophages at different  
activation statuses. PRRSV infection induced differential cytokine responses in MФs polarized  
with different mediators (Fig. 2). For example, MaV-IFNα and M1-IFNγ cells were more  
responsive than IFNβ-activated and M2-IL4 cells in the production of proinflammatory  
cytokines including IL-1β, IL-6, IL-8, IL-12, and TNFα. In contrast, IFNβ-activated cells were  
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most responsive in producing IL-10 upon vi rus infection. Although M2-IL10 cells were  
intermediate, M2-IL4 cells were rather inactive in cytokine production upon PRRSV infection  
(Fig. 2). Interestingly, both IL-8 and TNFα were not appreciably altered by PRRSV infection in  
macrophages at any activation status (Fig. 2). Thus, porcine macrophages at different activation  
statuses responded heterogeneously to PRRSV infection with respect to cytokine production.     
  
Macrophage and dendritic cells at different activation statuses differ in their  
permissiveness to PRRSV infection  
If PRRSV affects macrophage activation statuses via regulation of cytokine production, then  
does activation status of monocytic cells influence PRRSV infection?  In pigs, subsets of lung  
MФs and mDCs are the primary cells supporting PRRSV infection, and PRRSV infections  
frequently promote anti-inflammatory cytokine IL-10 production but suppress proinflammatory  
cytokines such as IL-12 (20-22). Using porcine monocytic cells polarized in vitro, we tested if  
PRRSV infection was altered in cells at different activation statuses.  PRRSV-infection was 
monitored using antibody to the PRRSV N protein and quantified using flow cytometry (33,34).  
M2 polarization with IL-4 and IL-10 increased the cell population that was permissive to PRRSV  
infection by 10-20% in both MФs and mDCs (Fig. 3). M1 polarization with LPS and IFN-γ  
showed a slight decrease in the population of permissive cells. Although both IFNα and IFNβ  
have been shown to induce antiviral states (12-15), only IFNα and not IFNβ significantly  
suppressed PRRSV infection in MФs (Fig. 3 and Table 3). IFNα also inhibited PRRSV  
replication in cells showing a tenfold decrease in fluorescence intensity of labeled PRRSV N  
proteins (Fig. 3). In addition, we also monitored the expression of CD163, a scavenger receptor  
critical to PRRSV cell entry, and a M2-IL10 cell marker (2,26).  IL-10 significantly up-regulated  
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CD163 expression in mDCs (Fig. 3). GM-CSF and M-CSF, two colony-stimulating factors  
involved in priming the early phase of differentiation in monocytic cells, increased MФs and  
BMs that were permissive to PRRSV infection by approximately 20% (Table 3). In summary,  
porcine monocytic cells at different activation statuses not only respond but also are different in  
their permissiveness to PRRSV infection (Fig. 2 and  3).  Because PRRSV infection may  
inevitably alter the cytokine response in porcine monocytic cells (Fig. 2), it is likely that the virus  
may co-opt the cell activation status to promote virus infection and exacerbate disease  
development in vivo.      
Gene ontology analysis indicates that IFN signaling and lipid metabolism is significantly  
regulated in macrophages at different activation statuses  
For functional classification of DEGs from RNA-Seq data, we used gene ontology (GO) analysis  
to obtain expression patterns of DEGs annotated to given GO-terms in the database  
(http://www.geneontology.org/).  Collectively, DEGs of each activation status could be  
annotated to 493 to 1,970 GO-terms; the most significant (correct p<0.05) GO-terms enriched by  
the DEGs included immune system process, immune response, antigen processing and  
presentation, fatty acid/lipid metabolic process, and IFN-signaling related to antiviral responses.    
Because deviation of the IFN-system has been well demonstrated in PRRSV infection and a  
potential target for antiviral regulation (7,10,12,13,15,21), we first analyzed DEGs related to the 
IFN-system, particularly type I IFN production and action in macrophages at differential  
activation statuses.  In pigs, PRRSV strains exerted differential ability to inhibit the production  
and action of type I IFNs, particularly in IFNα rather than IFNβ subtypes (21-25,34). We  
previously showed that the swine genome contains at least 39 f unctional genes encoding 7  
subtypes of type I IFNs, including multiple members of IFNα, IFNδ, and IFNω as well as a  
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single IFNβ gene (34). Emerging evidence shows that different subtypes of type I IFNs and even  
members of same subtype could be differentially responsive to viral infection (34,42).  Using 
RT-PCR assays, we showed that during the early phase (<6 h post-infection) of PRRSV infection  
in primary macrophages, the significant increase of IFNβ expression was accompanied with  
modest stimulation and even suppression of multiple IFNα, IFNδ, and IFNω subtypes (34 and Y.  
Sang, data not shown).  Here using RNA-Seq analysis we show that except for IFNβ, which had  
a relatively higher expression than other IFN subtypes, isoform transcripts of the other subtypes  
were only slightly detectable, with few read counts and differential expression in cells at  
different activation statuses, compared to average RPKM values of 10-40 of other cytokine genes  
such as TNF (Fig. 4A).  For example, IFNα1, IFNβ, IFNω2, and IFNω6 were detected in cells at  
the M1-IFNγ status, but IFNα5, IFNβ, IFNδ7, and IFNω4 were found in cells at the MaV-IFNα  
status.  In contrast, fewer isoforms of type I IFNs were detected in cells at M1-LPS, M2-IL4, and  
M2-IL10 statuses.  As expected, the highest expression of IFNβ was detected in cells at the M2- 
IL10 regulatory status (Fig. 4A).  Differential suppression of the IFN-system (both type I and  
type II IFNs) during the early phase PRRSV infection was also demonstrated using GO analysis,  
and DEG cluster frequency of general cytokines was much higher than those of IFN production  
and response (Fig. 4B). Detail mapping of IFN receptors and other IFN-stimulated/induced genes  
(ISG or IFI) indicated that they retained higher expression in cells at the M1-IFNγ and MaV- 
IFNα statuses, and were frequently suppressed at the M2-IL4 status (Fig. 4C and 4D). For  
example, we analyzed IFN stimulation of the guanylate binding protein (GBP) family, which is  
located within the region of swine chromosome (SSC) 4 and was recently genetically associated  
with pig anti-PRRSV immunity (43). Here we show that all porcine GBP genes, except an  
uncharacterized GBP2L, were highly expressed in the macrophages upon both IFNα and IFNγ  
18 
 
stimulation (Fig. 4D). Interestingly, we also detected a significant hypothetical transcript  
(GBPhp), clustered within porcine GBP region (Gene ID: 100524372 in current swine genome  
assembly Sscrofa10.2), whose expression correlated negatively with IFN-stimulation of porcine  
GBP genes (Fig. 4D).  Thus, the general suppression of gene expression in the IFN-system,  
particularly in IFN production, accompanied acute PRRSV infection in porcine macrophages,  
particularly at the M1-LPS and other M2 activation statuses (7,10,13,15,21).   
  
Using GO analyses we determined lipid-related biological processes enriched by DEGs and their  
differential response in macrophages at different activation statuses upon PRRSV infection (Fig.  
5 and Table 4).  In general, DEGs associated with different activation statuses could be assigned  
to 14−56 GO-terms pertinent to the processes of lipid/fatty acid biosynthesis, metabolism and  
transport (Table 4). These total numbers of enriched GO-terms were positively relevant to the  
DEGs numbers filtered out at each activation status.  For example, M1-LPS status and M2-IL10  
status had the highest (4667) and lowest (153) number of DEGs, so were correspondingly  
enriched in lipid-related GO-terms at the largest of 56 and the smallest of 14, respectively (Table  
4). However, statistical analyses of the significance of DEGs enriched in these lipid-related  
biological processes indicated that despite comparable GO-terms classified at the MaV-IFNα  
state, no term was significantly enriched by DEGs (Table 4 and Fig. 5B).  This finding indicated  
that lipid metabolic processes were generally arrested in macrophages at the MaV-IFNα state.  
Further annotation of the key genes encoding enzymes catalyzing lipid metabolic processes  
indicated that most had relatively suppressed expression at the antiviral state (44). These  
suppressed key genes in lipid metabolism included FASN (encoding fatty acid synthase, key gene  
for fatty acid synthesis), LIPE (encoding hormone-sensitive lipase, key gene for lipolysis),  
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HMGR (encoding 3-hydroxy-3-methylglutaryl-coenzyme-A reductase, key gene for sterol  
synthesis), and particularly ACC1 (encoding acetyl-CoA carboxylase alpha, key gene for fatty  
acid oxidation) (Fig. 5A). Cholesterol metabolism was recently implicated in regulation of viral  
replication, and some cholesterol derivatives were shown to have direct antiviral activity (44,45).  
As clearly shown in Figure 5A, genes of most, if not all, key enzymes in cholesterol metabolism  
were significantly differentially regulated among cells at different activation statuses upon 
PRRSV infection.      
  
Modulation of the activation status of monocytic cells using a lipid mediator suppressing  
PRRSV infection  
For translational research based on pr ofiling of gene response pathways, we are interested in  
developing a system to modulate the monocytic activation paradigm to aid in the management of  
PRRS (25,46,47). We began our investigation by targeting pathways that modulate 
inflammation, antiviral states and T-cell proliferation. Because of the importance of lipid  
signaling in regulation of inflammation and overall immune responses, we first screened  
mediators that regulate lipid metabolism (48-50). Among multiple selected agonists and  
antagonists for enzymes in lipid metabolism, 5-(tetradecyloxy)-2-furoic acid (ToFA), a  
competitive inhibitor of acetyl-CoA carboxylase (ACC) (40), significantly suppressed PRRSV  
infection in all tested cells (Fig. 6A) with 90% effective concentration (EC90) and toxicity in  
terms of 50% cytotoxic concentration (CC50) at 6 a nd 25 μg/ml, respectively in MARC-145  
cells.  ToFA at 5 μg/ml suppressed approximately 80% of PRRSV infection in MARC-145 cells  
(a monkey cell line sensitive to PRRSV infection), and up to 50% in both porcine alveolar MФs  
and mDCs (Fig. 6A). Suppression of PRRSV infection in cells by ToFA treatment was also  
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determined based on viral titers and viral replication to compare between samples collected from  
ToFA-treated and the control cells. Dose-dependent assay showed that cells treated with ToFA at  
5-10 μg/ml for 30 h s ignificantly suppressed viral infection with respect to virus titers and viral  
genome replication (Supplemental Figure S3).    With respect to PRRSV-induced cytokine  
production, ToFA treated MФs showed increased production of IL-1β, IL-8, IL-12, and IL-10,  
partially resembling IFNα- or IFNβ-treated cells (Fig. 6B). ToFA-treated MФs also displayed the  
lowest response in IL-4 production. These data suggest that ToFA may have the potential to  
skew cells toward an antiviral / M1 status. Consistent with a recent findings using mouse DCs  
(40), we also observed that ToFA-treated mDCs stimulate proliferation of blood T-cells much  
better than the control cells (Y. Sang, unpublished data). These findings indicate that ToFA,  
through depletion of lipid content or alteration of lipid signaling (40), skews activation statuses  
by generally favoring antiviral or antigen presenting processes, which may be similar to cells at  
the MaV-IFNα state (Fig. 6).   
  
Molecular modulation of the activation status of monocytic cells using IFN-expressing  
PRRSV to suppress co-infected viruses  
To potentiate antiviral immunity within the context of the porcine monocytic cell activation  
paradigm, a molecular tool was needed. One molecular tool that we developed is an IFN- 
expressing PRRSV infectious cDNA clone (37,51). Using this PRRSV cDNA vector, we have  
stably expressed immune effectors including multiple type I IFNs (37). The production of type I  
IFNs is fundamental to antiviral immunity and is suppressed in PRRSV infection (Fig. 4) (21- 
24). We reasoned that PRRSV replication-mediated IFNα production in situ would reverse IFN  
subversion by wild-type viruses. We believe that this construct is a prototype for molecular  
vaccines to simultaneously optimize an antiviral state and to present viral antigens. However,  
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because pigs have at least 39 functional type I IFN genes with diverse antiviral activity (34),  
which one should be used? We chose IFNα6 as our first candidate, because it has high antiviral  
activity against PRRSV (34). Another question we confronted is how can sufficient PRRSV  
replication activity be achieved when expressing an IFN with high PRRSV antiviral activity? We  
approached this problem by inserting a leader linker in front of the IFN coding region that  
encodes a l eader linker containing a C-terminal cleavage site of an endogenous protease  
expressed in MФs (Fig. 7A) (52). Using the designed construct, we were able to express and  
release active IFN peptides as well as rescue sufficient virions in MARC-145 cells (Fig. 7B)  
(37). In porcine MФs virus-replication competent expression of the full length peptide (with  
signal peptide, IFN-α6f), but not the mature IFNα6 peptide (without signal peptide, IFN-α6m),  
efficiently inhibited the infection of co-infected PRRSV (Fig. 8).  This was not unexpected  
because IFN peptides need the signal peptide included in the full-length construct for correct  
processing and secreting extracellularly to act on IFN receptors (IFNAR1/2) located on the  
plasma membrane (12, 15). This finding indicates that the correct partition of the expressed IFN  
by the signal peptide is essential for IFN antiviral activity. This was further confirmed when 
virus expression resumed after a protease inhibitor (Pep. A) was added, likely by competitively  
inhibiting the release of the IFN peptide from the linker. Macrophages infected with the virus  
expressing the full length IFNα6 were able to clear the virus infection and were protected from  
virus-induced cytolysis for 96 h  of co-infection. In contrast, cells infected with the virus  
expressing the linked mature peptide of IFNα6 could not prevent virus replication and cytolysis  
(Fig. 8E and 8F). Quantification of virus titers and viral genome transcripts also indicated an  
efficient replication of the IFN-expressing PRRSV particularly in MARC cells (virus titers of at  
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10-103 TCID50/ml, Supplemental Figure S4) and significant suppression of PRRSV infection by  
the replication-competent expression of the full-length of porcine antiviral IFN-α6 (Fig. 8G).   
  
DISCUSSION  
Our studies here integrate antiviral regulation into the paradigm of activation statuses in porcine  
monocytic cells, a group of immune cells that are not only critical for overall immune responses  
but are also targeted by numerous economically devastating viruses to evade antiviral immunity  
(16-19,21). These monocytotropic viruses include many of the world’s most dreaded porcine  
viruses, such as African swine fever virus (ASFV), classical swine fever virus (CSFV), porcine  
circovirus-2 (PCV2), foot-and-mouth disease virus (FMDV), pseudorabies virus (PrV), swine  
influenza virus (SIV) and the focus of our studies, PRRSV (19,21,24,36). These viruses 
collectively cause the majority of swine viral infections and significant global economic losses.  
Because of the lack of an effective vaccine, PRRSV has devastated swine herds worldwide for  
more than 20 years with an estimated loss nearing $800 million annually in the U.S. (43).  
Furthermore, this porcine virus evolves rapidly to form novel, highly pathogenic strains, causing  
new pandemic threats such as the highly pathogenic PRRSV first seen in China in 2006 (30,44).  
Activation statuses of monocytic cells regulate inflammation, tissue repair, antimicrobial  
activity, and T- and B-cell responses (1-5).  Here we integrate antiviral regulation within the  
activation paradigm of monocytic cells. Studies have shown that PRRSV directly infects  
subgroups of MФs and DCs and diverts immune responses in these cells through suppression of  
type I IFN production/action and impairment of antigen presentation (20-26). Therefore,  
understanding the activation status of monocytic cells and their interaction with PRRSV  
infection is essential not only to porcine immunology, but also to determine the immunological  
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etiology underlying PRRS (20-22,25,46,47) and providing a framework for immunometabolic  
modulation to potentiate antiviral immunity in vivo (21,47).  F ollowing standard procedures  
established in our laboratory, we defined that the macrophage population typically comprises  
>90% pulmonary lavage cells and showed a functional macrophage phenotype with respect to  
cell morphology, and bacterial and phagocytic activity (35). The mDCs were differentiated  
following a standard protocol, which has been well determined for their morphology and surface  
phenotype of MHC I+, MHC II+, and CD11c+ as well as low expression of CD16, CD14 and 
CD80/86 (36). Porcine blood monocytes were recently grouped based on the surface expression  
of CD14, CD163 and SLA DR (38); clearly, monocytes used in this study contain predominant  
CD14+CD163low cells (>90%) and few CD14+CD163high (6%) cells (See Supplemental Figure  
S5A).  In addition, we determined the secreted cytokine profile of these monocytic cells at basal  
and stimulated statuses, which further define their cell phenotypes pertaining to functional  
property.  Further, macrophages and mDC used in this study showed 70-94% permissiveness to  
PRRSV infection, which indicates their macrophage and mDC phenotypes because these  
monocytic subsets are predominant cell types known to support PRRSV infection (26).       
  
The activation status of porcine monocytic cells has not been systematically studied as compared  
to the well-characterized paradigm in humans and mice; although, a few previous studies have  
shown that the origin and differentiation of these cell lineages affects susceptibility to PRRSV  
(27,28).   Using primary monocytic cells isolated from the lungs and blood of naïve piglets, we  
showed that porcine monocytic cells could be polarized into different activation statuses with  
typical mediators characterized in other species. Although some cell-specific responses were  
noted, such as higher production of IL-8 in activated monocytes and diminished production of  
IL-12 in mDCs, in general, secretion of typical cytokines correlated with their phenotypes (Table  
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1).  Though studies of activation statuses in monocytes and DCs are limited, the M1and M2  
activation paradigm appears to be active in both monocytes and DCs (6-9).  In particular, we  
showed here that the antiviral states induced by type I IFNs, especially IFNα, fit the paradigm of  
activation statuses, and generally elicited more M1 statuses than M2 statuses. Interestingly, the  
cytokine profile of macrophages responding to IFNβ stimulation was more similar to the IL-10  
regulatory status, indicating that IFNβ may have less antiviral but more immunomodulatory  
activity than IFNα in macrophages (15) (Table 1 and Fig. 1A and Fig. 2).     
To study antiviral responses in cells at different activation statuses, we infected porcine  
macrophages with a PRRSV strain and investigated the early gene response (5 h post-infection)  
in cells polarized in vitro. We showed that during interaction with the virus in this early phase,  
macrophages kept their original polarization and cell integrity without any observed loss of  
viability, which allowed us to investigate early immunometabolic responses prior to cellular  
exhaustion by viral replication and release. Using PRRSV-infected macrophages at different  
activation statuses, we verified the expression of most cytokines and their receptors at the  
transcriptomic level.  In addition, novel status-specific identifiers such as IL10RA and CCL21 at  
the M1-IFNγ status where identified, which might reflect novel signature genes (Table 2 and  
Supplemental Figure S1). Similarly, the signature expression of chemokines and their receptors  
as well as TLRs were also characteristically correlated with different activation statuses (Table 2  
and Supplemental Figure S1). Of the key genes characterized for each activation status in  
macrophages, we showed most if not all typical signature genes specific to each activation status  
that have been characterized in other species were conserved in pigs. In particular, the marker  
genes related to the onset of antiviral states fit well into the paradigm of macrophage activation  
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statuses; together they can be incorporated into a framework linking antiviral regulation to  
immune homeostasis in monocytic cells (Fig. 1A).   
  
To reveal genes critical to status-specific antiviral and immune-homeostatic regulation, we  
compared response genes or gene response pathways among the PRRSV-infected macrophages  
at different activation statuses. In this context, we genome-wide profiled potential signature  
genes of those that were significantly up-regulated (Fig. 1B) or down-regulated in each 
activation status. Detailed annotation of those potential signature genes revealed some common  
signature genes (such as LIF and CD1B for M1 and M2 statuses, respectively) characterized in 
other species and novel discoveries including many undefined non-coding RNAs (Fig. 1B).   
However, most of these genes have not been studied for regulation of activation statuses and  
antiviral immunity. Therefore, our collection of potential signature genes pertinent to PRRSV- 
infected macrophages at each activation status provides a rich resource for targeting molecular  
regulation of the antiviral response in the paradigm of activation statuses.       
  
Characterizing signature genes for macrophage activation statuses also allowed us to  
demonstrate the consequence of interaction between PRRSV and MФ activation statuses (Fig. 2  
and Fig. 3).  PRRSV infection induced differential cytokine responses in macrophages at  
different activation statuses, indicating that the potential of PRRSV to re-polarize monocytic  
cells and the population sizes of macrophages at different activation statuses was a factor in  
determining MФ-initiated immune responses (16-18).  Notably, the high cytokine response of  
IL-1β, IL-6 and IL-12 was found at the MaV-IFNα or M1-IFNγ status, and a moderate response  
was found at the M2-IL10 status; whereas, macrophages at M2-IL4 and M1-LPS statuses, which  
mimic parasitic and bacterial infection, respectively, were the least responsive to PRRSV  
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infection (Fig. 2).  Conversely, we showed that the magnitude of cytokine response was  
somewhat reciprocal to cell permissiveness toward the PRRSV virus. For example, both M2-IL4  
and M1-LPS had a higher portion of PRRSV-infected cells than the two IFN-stimulated statuses.  
However, monocytic cells at M2-IL10 status had the highest ratio of permissive cells, which was  
perhaps because of their anti-inflammatory state and higher expression of the scavenger  
receptor CD163, a confirmed cellular receptor for PRRSV for infection (26). Interestingly, IFNβ  
at the same dose of IFNα stimulated IL-10 production (Fig. 2) and, in turn, had little suppressive  
effect on PRRSV infection in macrophages (Fig. 3 and Table 3). The regulation of IFNβ in IL-10  
production was recently shown in both macrophages and DCs, indicating the critical role of  
IFNβ in regulation of immune homeostasis in addition to its antiviral stimulation (53, 54).  
Although CD163 has been shown to be a cellular receptor capable of mediating PRRSV 
infection, its expression level in porcine monocytic cells was not always proportionally 
correlated with PRRSV permissiveness.  F or example, MaV-IFNα macrophages had twofold 
more CD163-positive cells but were only half as permissive to PRRSV compared with the M1- 
LPS macrophages (Table 3). Indeed, annotation of our RNA-Seq data showed that CD163 had a  
constitutive expression level (the lowest RPKM at 113.4 o f the M1-LPS-M1 compared with  
average RPKM values of most genes at 10-40), indicating that expression of CD163 in porcine  
monocytic cells is not a limiting factor (but could be an additive factor, such as at the M2-IL10  
status) for PRRSV infection (26).  In porcine macrophages, CD163-specific antibody blocked up  
to 75% of PRRSV infection, whereas a combination of both antibodies to CD163 and  
sialoadhesin completely blocked the infection (55). Notably, our two-color fluorescence 
facilitated flow cytometric analyses detected highly positive cells pertaining to the expression  
levels of PRRSV N-protein and directly immunolabeling cell CD163; therefore, some portion of  
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the “negative” staining cells should be critically determined as CD163low cells. Previous studies  
reported 60%-95% CD163-positive cells in porcine alveolar MФs using indirect  
immunodetection of CD163 (26, 55). To study CD163 expression dynamics and correlate CD163  
expression data detected using either direct or indirect immunodetection, we applied both  
detection procedures in alveolar MФs at different culture and activation states. As shown in  
Supplemental Figure S5B, while indirect immunodetection generally stained 60-80% alveolar  
MФs to be CD163-positive, which is close to previous results (26, 55), the direct  
immunostaining using FITC-conjugated CD163 mAb only detected 5-15% of CD163high cells,  
which is consistent with our evaluation using flow cytometric procedure in Figure 3 and Table 3.  
Dynamically, primary alveolar MФs prior to culture had much less CD163-positive cells (2-5%  
by indirect immunostaining), the 30 h-culture condition dramatically elevated CD163-positive  
cells over 10 fold to 40-50% (55), and polarization mediators and PRRSV infection altered  
around 30% of overall CD163-positive cells.  Although we know of no study exactly evaluating  
how many CD163 molecules per cell are sufficient to mediate PRRSV entrance, we interpret that  
a low threshold is better than a high one relative to pathogenic success of the virus.  Thus, it is  
reasonable  that a PRRSV infection ratio being higher than CD163high cell population as shown  
in Table 3 (26,55).                 
  
In addition to genome-wide profiling of signature genes, gene ontology (GO) analysis of the  
DEGs identified multiple biological processes significantly and differentially altered by PRRSV  
infection in macrophages at different activation statuses. In this context, two biological  
processes, the IFN-system (IFN production and action) and the lipid metabolic process, were  
analyzed to target antiviral regulation. Suppression of the IFN-system typically has been  
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associated with PRRSV infection. Non-structural proteins (Nsp) of PRRSV, such as Nsp1,  
inhibit IRF3 and ISGF3 nuclear translocation, which result in suppression of both type I IFN  
production and induction of ISGs in host cells (21,24,25). Furthermore, differential suppression  
of IFNα rather than IFNβ subtypes of porcine type I IFNs by PRRSV infection was shown in  
mDCs (21,24,25).  Compared with other cytokine genes, many fewer reads pertinent to IFN  
transcripts were detected in our RNA-Seq data.  For example, RPKM values for all IFN subtypes  
were <1.0 except IFNβ at the M2-IL10 status; whereas, other cytokine genes generally had  
RPKM values averaging 10-40 (Fig. 4A).  Clearly, general suppression of type I IFN production  
by PRRSV in macrophages could be ascribed to the low detection of IFN transcripts.  In  
addition, an AU-rich element (ARE)-mediated mRNA decay could contribute the low detection  
of IFN transcripts (56).   Similar to their orthologs in humans, mRNA of most porcine type I  
IFNs contains an ARE in the 3’ untranslated region, and ARE-mediated mRNA decay is a  
critical mechanism in posttranscriptional control IFN level (56).  In this context, we observed  
that genes of several cellular proteins including KHSRP (KH-type splicing regulatory protein)  
and BRF2 (butyrate response factor), which control ARE-mediated mRNA decay (56), were  
stimulated in most PRRSV-infected cells (Unpublished data).  Determining whether PRRSV has  
a mechanism to suppress IFN production through the ARE-mediated mRNA decay mechanism  
should be pursued.  Although the low-read number of IFN transcripts did not attain a significant  
threshold between the cells at different activation statuses, comparison of IFN detected among  
different activation statuses demonstrated that IFN gene expression was different in cells at  
different activation statuses in terms of IFN subtypes and expression level.  This was indicated  
by the finding that more subtypes and higher IFN expression were detected at both MaV-IFNα  
and M1-IFNγ statuses.  Using current RNA-Seq analysis, it is difficult to estimate if PRRSV  
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infection inhibits IFN induction of ISGs; however, expression of most ISGs was much higher in  
PRRSV-infected macrophages at the MaV-IFNα status, implying that polarization of monocytic  
cells using exogenously delivered IFN is feasible for overcoming PRRSV suppression of IFN 
(37,57). In addition, macrophages at the M1-LPS status were inactive in terms of induction of  
most ISG expression upon PRRSV infection, indicating that bacterial co-infection could be a  
major factor that exacerbates the viral pathogenicity in PRRS (20,25).    
  
Multiple biological processes in lipid / fatty acid metabolism were significantly enriched by  
DEGs in GO analyses. In general, DEGs involved in most lipid biological processes could be  
detected in cells at all activation statuses except M2-IL10, which had a limited number of 153  
significant DEGs and enriched the fewest GO-terms. However, when a hypergeometric test was  
used to find significantly enriched GO terms in DEGs, we observed several lipid metabolic  
processes that were significantly altered in cells at all activation statuses except the MaV-IFNα  
status (Table 4). This likely indicates an arrest of lipid metabolism in the antiviral state induced  
by IFNα, or that modulation of cellular lipid metabolism may provide a means to simulate  
antiviral states (21,44). Profiling key genes involved in lipid metabolism revealed that the  
expression of genes encoding some critical enzymes, such as ACC1, FASN, LIPE and HMGR,  
was suppressed, particularly in the antiviral state (Fig. 5 and Table 4). Therefore, modulation of  
the activity of these enzymes may provide another approach to antiviral regulation (44,45,49,50).      
  
Based on RNA-Seq analyses, we validated our observations of gene expression with authentic  
antiviral regulation in cells. First, we tested a series of agonists or antagonists in regulation of  
lipid metabolic processes. ToFA, a competitive inhibitor of acetyl-CoA carboxylase (ACC),  
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showed significant activity in suppressing PRRSV infection in all tested cells. We also showed  
that ToFA at a physiological dosage elicited porcine macrophages to produce proinflammatory  
cytokines (including IL-1β, IL-8, TNF-α, and IL-12) as well as the anti-inflammatory cytokine  
IL-10, intermediately as seen in the antiviral state induced by IFNα and IFNβ (Fig. 6B). ToFA is  
a competitive inhibitor of acetyl-CoA carboxylase (ACC), which serves as a key enzyme in  
cellular lipid metabolism to catalyze malonyl-CoA production for new fatty acid synthesis  
meanwhile inhibiting the beta-oxidation of fatty acids in the mitochondria. Because lipid  
metabolic status is essential to fuel cell activation and some lipid metabolites also directly  
intervene in virus-host interaction, suppression of ACC by ToFA, thus, may affect viral infection  
directly via the virus infection process (such as viral fusion and budding processes) (37) and  
indirectly through regulation of cell antiviral status. Further lipidomic profiling will determine 
lipid metabolites altered by ToFA treatment in monocytic cells, However, the current study  
indicates that ToFA treatment may skew porcine macrophages to an antiviral state  similar to  
what happens in cells stimulated with type I IFNs with respect to inflammatory cytokine  
production (Fig. 6B) and suppression of lipid metabolism (Fig. 5 and Table 4). In addition, ToFA  
treatment was shown to enhance DC processing of antigens for activation of T cells in mice (40); 
a similar mechanism should be considered for vaccine design and validation in pigs. These  
findings indicate that an activation status with virostatic potency could be induced through  
modulation of cellular lipid metabolism (40,44,49,50).    
  
Exogenous application of type I IFNs, particularly the IFNα subtype, has been used successfully  
for treatment of several viral diseases (12-15). Several studies reported that suppression of type I  
IFN production was a key mechanism that contributed to success of PRRSV field isolates, and  
that some attenuated strains showed less suppression and even stimulation of IFN production  
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(21,24,25,46,47). Based on m echanistic studies of the interaction between PRRSV and the  
porcine IFN system, we and others have proposed reversing type I IFN suppression at infection  
sites to combat PRRSV infection (21,47,57). For example, in two reports, IFNα was introduced  
either intramuscularly as a cDNA adjuvant component (58) or an adenoviral expression construct  
(57); although the former showed little synergistic effect for vaccine protection, the timely virus- 
vector mediated IFNα expression alone successfully protected against PRRSV challenge (57,58).  
We therefore suggest that a type I IF N expressed by a replication-competent PRRSV cDNA  
infectious clone may be an ideal means for reversing PRRSV-suppression of type IFN  
production (21,37).  We were able to express different subtypes of type I IFNs, including IFNα1,  
IFNα6, IFNδ3, and IFNω5 with a PRRSV cDNA infections clone, and showed that the  
replication-competent PRRSV-IFN constructs expressing the IFNα subtype induced antiviral  
protection in cells (37).  To obtain sufficient PRRSV replication while expressing an IFN with  
high PRRSV antiviral activity, we inserted a leader linker in front of the IFN coding region. This  
design allowed for rescue of enough virions in MARC-145 cells, and the release of active IFN  
peptides in porcine MФs to overcome the virus suppression of IFN production (Fig. 8 and  
Supplemental Figure S4). This construct can be a prototype for molecular vaccines to optimize  
an antiviral state and to simultaneously present viral antigens.   
  
Several studies have reported genome-wide gene response pathways directly in porcine tissues or  
cell collections (30,43). Our use of RNA-Seq to profile signature genes and responsive pathways  
associated with PRRSV infection in subsets of monocytic cells, not only confirmed previous  
identifications and revealed novel gene response pathways, but also examined their involvement  
in antiviral regulation through pharmaceutical and molecular manipulation.  Our efforts now will   
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be to introduce a modified lipid nanoparticle (LNP) procedure (59) to deliver both ToFA (as an  
adjuvant) and the PRRSV-IFN construct as vaccine platform in pigs to further validate the  
vaccine effect of ToFA and the PRRSV-IFN expression construct in vivo.    
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Table 1. Cytokine response corresponding to porcine monocytic cell activation statuses*   
  
Mediator IL-1β  IL-6  IL-8  IL-12  TNF-α  IL-10  
Macrophages (MФs)  
LPS    6.3 ± 0.6* 0.9 ± 0.1 3.9 ± 0.4* 1.0 ± 0.0 1.2 ± 0.1 1.0 ± 0.0 
IFN-γ   2.0 ± 0.2* 1.8 ± 0.2* 1.4 ± 0.1 8.1 ± 0.8* 1.0 ± 0.1 2.2 ± 0.2* 
IL-4     -1.8 ± 0.2* -1.4 ± 0.2 -2.3 ± 0.2* 1.0 ± 0.0 -1.1 ± 0.1 1.0 ± 0.0 
IL-10   -3.0 ± 0.3* 1.2 ± 0.2 -5.0 ± 0.5* 5.7 ± 0.5* -1.4 ± 0.1 2.4 ± 0.2* 
IFN-α    1.6 ± 0.1 1.6 ± 0.2 1.7 ± 0.2* 6.9 ± 0.7* -1.5 ± 0.1 1.7 ± 0.2* 
IFN-β     -1.5 ± 0.1 1.2 ± 0.1 -4.6 ± 0.4* 4.1 ± 0.4* 1.2 ± 0.1 2.6 ± 0.2* 
       
Monocytes (BMs)  
GM-CSF     3.3 ± 0.1* 2.1 ± 0.1* 3.6 ± 0.0* n.d. 1.6 ± 0.4 6.9 ± 1.1* 
M-CSF   2.8 ± 0.1* 1.4 ± 0.1 12.5 ± 0.1* n.d. 2.3 ± 0.6* 7.1 ± 1.2* 
       
Monocyte-derived dendritic cells (mDCs)  
LPS    1.8 ± 0.2* 1.6 ± 0.2 3.3 ± 0.3* n.d. -2.7 ± 0.3* -4.2 ± 0.4* 
IFN-γ   1.2 ± 0.1 1.1 ± 0.1 2.3 ± 0.2* n.d. -1.2 ± 0.1 1.0 ± 0.0 
IL-4     -1.9 ± 0.2* 2.3 ± 0.3* 6.3 ± 0.6* n.d. -1.6 ± 0.2 -1.4 ± 0.1 
IL-10   -8.3 ± 0.8* 1.0 ± 0.0 -1.9 ± 0.2* n.d. -2.1 ± 0.4* 2.1 ± 0.2* 
IFN-α    1.7 ± 0.2* 1.0 ± 0.0 2.6 ± 0.2* n.d. -1.3 ± 0.1 1.0 ± 0.0 
IFN-β     1.9 ± 0.2* 1.0 ± 0.1 3.5 ± 0.3* n.d. -1.1 ± 0.1 1.1 ± 0.0 
* Cells were stimulated with the mediators (20 ng/ml, except GM-CSF at 50 a nd M-CSF at 100 ng/ml in PBS  
containing 5% BSA) for 30 h , then thoroughly washed and replenished with fresh medium for 16h. Culture  
supernatants were collected and cytokines were measured. Data are means ± SE of three replicates, *p < 0.05  
relative to the control.   
  
  
  
  
  
  
  
  
  
  
39 
 
Table 2.  Cytokine and cytokine-receptor genes significantly regulated in macrophages at different  
activation statuses*.   
*p(FDR) < 0.001, fold change >2 for significant determination.  G ene symbols are according to NCBI Gene  
database at http://www.ncbi.nlm.nih.gov/gene/, bold indicates those up- or down-regulated only in the indicated  
status but not in other statuses.  
  
  
  
  
  
  
  
  
   
Status Up-regulated genes Down-regulated genes 
IFNγ-M1 IL1B, IL4RA, IL6, IL7, IL8, IL10RA, IL12A, IL12B, 
IL12Rb1, IL13RA, IL15, IL15RA, IL17RC, IL18, 
IL18BP, IL23RA, IL27A, TNF, TNFAIP1, CSF2RA, 
CSF3, CCL2, CCL4, CCL5, CCL8, CCL20, CCL21, 
CCL23,  CXCL9, CXCL10, CXCL11, CXCL16, 
CCR2L, CCR5, CCR7 (Total: 35) 
IL1A, IL2RG, IL6RA, IL7RA, CSF1R, 
CSF2RB, CCL17, CCL19, CCL22, CCL24, 
CXCL4, CXCL14, CXCR2, CXCR4 (Total: 
14) 
IL4-M2 IL4I1, IL7, IL7RA, IL10, IL17RA, IL17RB, IL17RC, 
IL18, IL23RA, IL27RA, CSF1R, CSF2RA, TGFB, 
CCL5, CCL8, CCL17,  CCL22, CCL24, CXCL16, 
CCR7, CXCR2, CXCR2L (Total: 22) 
IL1A, IL1B, IL2RG, IL8, IL13RA, TNFAIP1, 
CSF3,  CSF2RB, CCL2, CCL3, CCL4, 
CCL23, CXCL2, CXCL4,  CXCL10, 
CXCL14, CCRL2, CCR5,  CXCR4 (Total: 19) 
LPS-M1 IL1A, IL1B, IL1E,  IL1RN, IL1R2, IL2RA, IL5, IL7, 
IL8, IL10,  IL12A, IL12B, IL18, IL18BP, IL19, 
IL23P19, IL27A, IL27B, IL33,  TNF, TNFAIP1, 
CSF3, CCL2, CCL3, CCL4, CCL5, CCL8, CCL17, 
CCL20, CCL22, CCL23, CCL24, CXCL2, CCR7, 
CXCR2 (Total: 35) 
IL2RG, IL4RA, IL6RA, IL7RA, IL11RA, 
IL13RA, IL15RA, IL16, IL17RA, IL17RC, 
IL17RE, IL23RA, IL27RA, CSF1R, CSF2RA, 
CSF2RB, TGFB, CCL21, CXCL4, CXCL10, 
CXCL14, CXCL16, CCRL2, CCR5, CXCR4 
(Total: 25) 
IL10-M2c IL4RA,  IL6RA, IL7, IL7RA, IL8, IL10RB,  IL13RA, 
IL15RA,  IL18, IL18BP, IL21R, IL23RA,  IL27RA,  
TNFAIP1, CSF1R, CSF2RB, CCL23, CXCL2, 
CXCL4, CXCL16, CXCR4 (Total: 21) 
IL1A, IL1B, CSF2RA, CCL3, CCL4, CXCL10 
(Total: 6) 
IFNα-MaV  IL1RN, IL2RG, IL4I1, IL6RB,  IL7, IL7RA, IL10, 
IL12Rb1, IL15, IL15RA, IL17RA,  IL18BP, IL21R, 
IL27A, IL27B,   TNFAIP1, CSF2RA, CCL2, CCL4, 
CCL5, CCL23, CCL25, CXCL9, CXCL10, CXCL11, 
CXCL13, CXCL16, CCR2L, CCR5, CCR7 (Total: 30) 
IL1A, IL1B, IL1R2 , IL8, IL10RA, IL10RB,  
IL13RA, IL17RC, IL18, IL23RA, CSF3, 
CSF1R, CSF2RB, TGFB, CCL3, CCL8, 
CCL17, CCL24, CXCL2, CXCL4, CXCR1, 
CXCR2, CXCR4 (Total: 24) 
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Table 3. Regulation of PRRSV infection and expression of CD163 by activation mediators*   
  
% 
 
PBS LPS IFN-γ IL-4 IL-10 IFN-α IFN-β GM-CSF M-CSF 
MΦs Virus (+) 68.1 ± 5.4 80.3 ± 7.5 67.6 ± 6.3 88.8 ± 8.2* 91.2 ± 8.5* 36.6 ± 3.4* 84.8 ± 8.0 89.1 ± 8.3* 88.1 ± 8.2* 
 
CD163high 15.0 ± 1.4 4.1 ± 0.4* 10.1 ± 1.0 10.2 ± 1.0 11.7 ± 1.1 8.2 ± 0.8* 8.2 ± 0.8* 10.4 ± 1.0 12.3 ± 1.2 
mDCs Virus (+) 69.5 ± 1.7 65.1 ± 6.1 55.0 ± 5.1 75.2 ± 7.0* 77.7 ± 7.3* 48.7 ± 4.5* 63.2 ± 5.9 - - 
 
CD163high 31.0 ± 2.9 37.0 ± 3.5 25.8 ± 2.4 16.3 ± 1.5* 56.3 ± 1.5* 22.4 ± 2.1* 23.2 ± 2.2* - - 
BMs Virus (+) 38.8 ± 3.6 - - - - - - 65.1 ± 6.1* 55.9 ± 5.2* 
 CD163high 5.1 ± 0.5 - - - - - - 13.4 ± 1.3* 10.2 ± 0.5* 
*Percentages are of 5,000 cells, partial list from Fig. 3. MФ, macrophage; mDCs, monocyte-derived dendritic cells;  
BM, blood monocyte. Data are means ± SE of four replicates, *p < 0.05 relative to the control.  
  
Table 4: Numbers of DEG-enriched terms in gene ontology (GO-term) analysis of lipid/fatty  
acid metabolism  
 
 
Total GO-
Terms 
Significant GO-Terms 
 
(p<0.5) (p<0.05) 
IFNγ-M1 49 7 3 
IL4-M2 39 5 1 
LPS-M1 56 6 5 
IL10-M2c 14 2 0 
IFNα-MaV  37 0 0 
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FIGURE LEGENDS  
  
Figure 1. (A) Integration of antiviral states into the macrophage activation paradigm.  
Macrophages (MФs) are capable of displaying different functional phenotypes under the stimuli  
of specific mediators. Four conventional subtypes of MФ activation statuses (M1, M2a, M2b and  
M2c) and antiviral states (MaV) are defined based on primary inductive mediators illustrated in  
the inner circle along with subtype-specific IRFs labeled in the cell. MФ polarization is  
associated with distinctive gene signatures selectively listed adjacent to the outer circle. As  
illustrated, most listed signature genes were identified and showed high expression  
corresponding to each activation status.  The underlined M2b status was not tested and porcine  
orthologs of CCL13 and CCL18 have not been identified thus far.  (B) Illustration of potential  
signature genes profiled using RNA-Seq. Potential marker genes were grouped based on  
significant upregulation only in one activation status, such as LPS- (along X-axis) or IL4- 
stimulated (along Y-axis) cells.  *p (FDR) <0.001, fold change ≥2 for significant determination.   
Key abbreviations: ACTH, adrenocorticotropic hormone; ARG1, agrinase 1; bIGH3, matrix  
associated protein betaIG-H3; COX, cyclooxygenase; DCSIGN, DC-specific intercellular  
adhesion molecule-3-grabbing nonintegrin; FN1, fibronectin 1; GC, glucocorticoid; GR, GC  
receptor; IFN-I/-III, type I or III interferon; iNOS, inducible nitric oxide synthase; IRF, IFN  
regulatory factor; ISG, IFN stimulated genes;  MRC1, mannose receptor C type-1; NA, nucleic  
acid; SPHK1, sphingosine kinase 1; RLR, RIG-I-like receptor; TLR, Toll-like receptor.   
  
Figure 2. Differential cytokine response to PRRSV infection in cells primed with different  
activation stimuli. Porcine alveolar MΦs were treated as in Table 1 and infected with PRRSV  
(SDSU28983) for 16h a fter 30h s timulation. Cytokine concentrations in culture supernatants  
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from the infected cells are plotted against those from uninfected cells as in Table 1. Data are  
means ± SE of three replicates, *p < 0.05 relative to the DPBS control.    
  
Figure 3. Effects of cell polarization on PRRSV infection. Cells were treated with the indicated  
mediators as in Table 1, t horoughly washed, and infected with PRRSV for 16h. C ells were  
collected and immunostained with specific mAbs for the PRRSV N protein (FL2: R-PE) and  
CD163 (FL1: FITC), a scavenger receptor critical for PRRSV infection and a signature marker  
for M2-IL10 activation. Positive cells were counted using flow cytometry.  Data represent a set  
of four independent assays as presented in Table 3.   
  
Figure 4. Quantitative expression and gene ontology (GO) analyses of interferon (IFN) 
production and action. (A) Quantitative expression analysis of type I IFN transcripts in PRRSV- 
infected macrophages at different activation statuses, showing suppressed type I IFN expression  
compared with the detection of TNF (tumor necrosis factor-α). (B) GO analysis of DEGs  
clustered with IFN production and action compared with DEGs cluster frequency to other  
cytokines, * and &, p < 0.05 compared with M0-PBS or among all statuses, respectively. (C)  
Heatmap of the differential expression of genes encoding IFN receptors and IFN- 
stimulated/induced genes (ISGs or IFIs). (D) Family-wide analysis of the expression of genes  
encoding guanylate binding proteins (GBPs), a group of ISGs recently shown to be potentially  
associated with PRRSV pathogenesis (42).  GBPhp is an unknown hypothetical gene, which  
formed into a gene cluster with all other porcine GBP genes in Chromosome 4 a nd had an  
expression pattern negatively correlated with most other porcine GBP genes.   T he color scale  
under each heatmap illustrates the midpoint and range of RPKM values of listed transcripts.  
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Figure 5. Heatmap and gene ontology (GO) analyses of the biological processes related to  
lipid/fatty acid metabolism. (A) Differential expression of key genes in fatty acid oxidation, fatty  
acid synthesis, lipolysis and sterol synthesis. (B) Significant biological processes of lipid/fatty  
acid metabolism enriched by DEGs in GO a nalysis. DEGs from MaV-IFNα state have no  
significantly enriched lipid metabolic pathways, implying an arrested state of lipid metabolism in  
macrophages at MaV-IFNα state (also see Table 3). *, p < 0.5 and **, p < 0.05 respectively.  
  
Figure 6. ToFA, a competitive inhibitor of acetyl-CoA carboxylase (ACC), suppresses PRRSV 
infection in cells (A) and modulates macrophage response to PRRSV infection with respect to  
cytokine production (B). Cells were stimulated with the mediators (IFN-α or IFN-β at 20 ng/ml,  
and ToFA, at 5 μg/ml) for 30 h, t hen washed and replenished with fresh medium containing  
PRRSV infected for 16h before counting PRRSV positive cells or collected medium for cytokine  
measurement as in Table 1. Data represent percentages of 10,000 c ells counted with flow  
cytometry (A) and averages of three independent assays (B).    
  
Figure 7. Conditional expression of antiviral interferon (IFN) using an infectious PRRSV cDNA  
clone. (A) Schematic of the vector promoter and the DNA encoding viral genome. The open  
reading frame of an antiviral IFN was inserted in the viral ORF1b/ORF2 junction region using  
two restriction enzymes (Afl II & Mlu I). The expressed IFN peptide has a leader of a His-tagged  
peptide containing a C-terminal protease cleavage site. This design allows rescue of high-titer  
recombinant virus in MARC-145 cells and IFN peptide release by the protease highly expressed  
in inflamed MФs. (B) Western blot shows successful expression and processing of the His- 
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tagged IFNα6 peptides. Cell lysates from MARC-145 cells infected with IFNα6-expressing  
PRRSV were treated (+) with 5 U of the protease and blotted with both anti-His-tag (1:1,000)  
and anti-IFN-α (1:200) antibodies (R&D). Note the loss of His-tag and reduction of ~2 kDa of  
the protein band in the protease treated samples. The image on the right shows merged His-tag  
(Red) and PRRSV (Green) immunofluroscence showing colocalization (Yellow) of IFNα6- 
PRRSV in the infected MARC-145 cells.   
  
Figure 8. Antiviral activity of a PRRSV cDNA infectious clone expressing porcine IFNα6. The  
expression of the full length of IFNα6 (IFN-α6f, with signal peptide) instead of the mature form  
(IFN-α6m, without signal peptide), protects alveolar MФs from infection and cytolysis by a co- 
infected PRRSV. The “●♦” symbol indicates a His-tagged linker of an endogenous protease  
cleavage site. Fluorescent images show co-infected GFP-labeled PRRSV and bright field images  
show cell cytolysis. (A1-B2) MФs co-infected with the IFN-α6m-expressed PRRSV and the  
GFP-labeled virus with (B) or without (A) addition of a protease inhibitor (Pep. A). (C1-D2)  
Same as in A and B but with IFN-α6f-expressed PRRSV showing suppression of co-infected  
GFP-PRRSV. (E1-F2) IFN-α6f-expressed PRRSV protects cells from infection and cytolysis  
after 96 h of co-infection with GFP-PRRSV. Data represent three repeats with similar results.   
(G) Suppression of PRRSV infection in macrophages by conditional expression of full-length  
IFN-α6. Virus containing medium and RNA were prepared from macrophages infected by GFP- 
PRRSV and IFN-expressing PRRSV for 96 h. The total viruses were titrated in MARC-145 cells  
to estimate TCID50 values; and the transcripts of PRRSV nucleocapsid (N) protein in total RNA  
(100 ng/20 μl PCR reaction) purified from the infected cells were detected using a real-time RT- 
PCR to calculate fold decreases relative to the GFP-PRRSV only control. *, p < 0.05 relative to  
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GFP-PRRSV only control.  The primers for RT-PCR detection were listed in the Supplemental  
Table S1.   
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